Bayer poachs another GSK executive to lead its strategic oncology business unit

Bayer has appointed Dr.

Both Tara Frenkl and Christine Roth were previously at GSK, with Frenkl previously serving as senior vice president and head of oncology drug development at GSK, while Roth was a senior GSK global oncologist before joining Bayer on March 1.

It is reported that Bayer's Prescription Drugs Division focuses on the field of cardiovascular diseases and is currently strengthening its foothold in the field of oncology, investing heavily in expanding research and development pipelines, and collaborating with a number of gene therapy companies

At Bayer, Roth and Frenkl will focus on developing the prostate cancer drug Nubeqa

Bayer's third-quarter 2021 results show that Nubeqa's sales have grown slowly and it did not make the top 20 drug list

Currently, Bayer is conducting clinical trials of Nubeqa in prostate cancer indications

Notably, Bayer's prostate cancer radiotherapy drug Xofigo is a powerful addition to Nubeqa and has been approved for the treatment of castration-resistant prostate cancer, symptomatic bone metastases and patients with no known visceral metastatic disease

Original in English: https:// href="https://" target="_blank">https://